Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, 02114, USA.
Circ Res. 2011 Aug 5;109(4):463-74. doi: 10.1161/CIRCRESAHA.110.225003.
Despite unmet needs for cardiovascular biomarkers, few new protein markers have been approved by the US Food and Drug Administration for the diagnosis or screening of cardiovascular diseases. Mass spectrometry-based proteomics technologies are capable of identifying hundreds to thousands of proteins in cells, tissues, and biofluids. Proteomics may therefore provide the opportunity to elucidate new biomarkers and pathways without a prior known association with cardiovascular disease; however, important obstacles remain. In this review, we focus on emerging techniques that may form a coherently integrated pipeline to overcome present limitations to both the discovery and validation processes.
尽管心血管生物标志物的需求未得到满足，但美国食品和药物管理局(FDA)仅批准了少数几种新的蛋白质标志物用于心血管疾病的诊断或筛查。基于质谱的蛋白质组学技术能够鉴定细胞、组织和生物体液中的数百到数千种蛋白质。因此，蛋白质组学可能有机会阐明新的生物标志物和途径，而无需预先与心血管疾病有已知关联；然而，仍然存在重要的障碍。在这篇综述中，我们专注于新兴技术，这些技术可能形成一个连贯的集成管道，以克服发现和验证过程中的现有局限性。
